Cancer Patents (Class 514/19.3)
  • Patent number: 11142561
    Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The University of British Columbia
    Inventors: Christopher J. Ong, James William Peacock, Martin E. Gleave
  • Patent number: 11117931
    Abstract: An antimicrobial peptide has the amino acid sequence of SEQ ID NO: 1, except that i) the 1st and the 14th amino acids are deleted, ii) the 4th and the 8th amino acids are substituted with lysine (K), iii) the 7th amino acid is substituted with leucine (L), iv) the 9th amino acid is optionally substituted with lysine (K), and v) the 12th amino acid is optionally substituted with lysine (K). A method for antimicrobial treatment in a subject including administering a pharmaceutically effective amount of the antimicrobial peptide to a subject.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 14, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
    Inventors: Yoonkyung Park, Min-Kyung Kim
  • Patent number: 11083774
    Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: August 10, 2021
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Laurence Zitvogel, Takahiro Yamazaki, Oystein Rekdal, John Sigurd Mjoen Svendsen
  • Patent number: 11045534
    Abstract: The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 29, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayuki Fujita, Fumiyoshi Okano
  • Patent number: 11028136
    Abstract: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 8, 2021
    Assignees: Sapporo Medical University, Medical & Biological Laboratories Co., Ltd.
    Inventors: Toshihiko Torigoe, Eri Atsuyama, Hironori Otaka, Kazue Nakano, Dongliang Li, Shingo Toji, Takuya Asano, Ryota Horibe, Yoshihiko Hirohashi, Noriyuki Sato, Tsuyoshi Saito
  • Patent number: 10987295
    Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: April 27, 2021
    Assignee: College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation
    Inventors: Ji-Hyung Chung, Da-Yoon Chung
  • Patent number: 10982259
    Abstract: Differential expression of long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) are used to monitor diseases and determine therapeutic efficacy in, for example, neurological diseases, inflammatory diseases, rheumatic diseases, and autoimmune diseases. Machine learning systems are used to identify lncRNAs or eRNAs having differential expression correlated with responsiveness to various therapies.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: April 20, 2021
    Assignee: IQUITY, INC.
    Inventor: Charles Floyd Spurlock, III
  • Patent number: 10981954
    Abstract: The present application provides an inhibitory compound, such as a peptide, and methods for using the inhibitory compound in the treatment, diagnosis or monitoring of cognitive and mood disorders that are typically associated with memory loss and/or loss of executive function. In one example, the inhibitory compound is a peptide that mimics the N-terminal sequence of the intracellular loop of ?5 subunit of ?5GABAA receptors. Also provided are compositions and methods for treating a disorder associated with memory loss or loss of executive function. The therapeutic method comprises the step of inhibiting binding of radixin to ?5GABAA receptors, for example, by administration of the presently described inhibitory compound or peptide.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 20, 2021
    Assignees: The Governing Council of the University of Toronto, Banting Institute
    Inventors: Gang Lei, Beverley Anne Orser
  • Patent number: 10960082
    Abstract: Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n??I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II, wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 30, 2021
    Assignee: NEWBIO THERAPEUTICS, INC.
    Inventors: Deqiang An, Nianhe Han, Di Zeng, Hang Yang, Peng Zhu, Mingzhen Li, Li Jian, Chun Yang
  • Patent number: 10905728
    Abstract: Extracts of Agaricus blazei Murill have been found to have anti-tumor activity. In particular, a polar, high molecular weight fraction of an Agaricus blazei Murill extract has been found which has an inhibitory effect on legumain activity. Extracts of Agaricus blazei Murill can be used in a pharmaceutical composition to inhibit cysteine protease legumain in a patient suffering from a tumor thereby treating the tumor and preventing new tumors.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 2, 2021
    Assignee: Immunopharma AS
    Inventors: Anne Berit Calmeyer Samuelsen, Lise Berven
  • Patent number: 10874678
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 29, 2020
    Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10845359
    Abstract: The present invention relates to a method for analyzing the activation state of a signaling pathway in a cell or tissue separated from a subject through real time single molecule protein-protein interaction analysis, and a method for selecting a personalized medicine or predicting a therapeutic efficacy to a medicine using the same.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 24, 2020
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae-Young Yoon, Hong Won Lee
  • Patent number: 10836795
    Abstract: A peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and a use of the peptide, are described. The peptide has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 17, 2020
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee, Joocheol Park
  • Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Patent number: 10782294
    Abstract: Isolated peptides and compositions comprising same are provided. Further, methods for targeting mitochondria in a cell, methods for assessing mitochondrial function in a cell and methods for diagnosing mitochondria associated diseases are provided.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 22, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Arnon Henn, Boris Shneyer, Andreas Reichert
  • Patent number: 10766942
    Abstract: The present invention provides an anti-angiogenic peptide comprising an amino acid sequence having at least 70% identity to amino acid residues 123-140 of SEQ ID NO 1 or amino acid residues 24-141 of SEQ ID NO 2. The invention also provides nucleic acid constructs encoding such peptides, and vectors and cells comprising such nucleic acid constructs. The invention further provides pharmaceutical compositions comprising the peptides or nucleic acid constructs of the invention, and the use of peptides, nucleic acid constructs or pharmaceutical compositions of the invention to treat diseases associated with angiogenesis.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 8, 2020
    Assignee: Queen Mary University of London
    Inventors: James Whiteford, Giulia De Rossi
  • Patent number: 10768179
    Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 8, 2020
    Assignees: National Cancer Center, Daiichi Sankyo Company, Limited
    Inventors: Takashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
  • Patent number: 10752893
    Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: August 25, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • Patent number: 10722593
    Abstract: Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed herein can be used to treat diseases such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 28, 2020
    Assignee: SIRENAS LLC
    Inventors: Oliver Booth Vining, Venkata Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Jacob Neal Beverage, Elizabeth Paige Stout, Bryan Junn Lee, Steven Bruce Cohen, Eduardo Esquenazi
  • Patent number: 10704082
    Abstract: Aspects of the technology disclosed herein relate to methods of preparing and analyzing nucleic acids. In some embodiments, methods for preparing nucleic acids for sequence analysis (e.g., using next-generation sequencing) are provided herein.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 7, 2020
    Assignee: ArcherDX, Inc.
    Inventors: Joshua Stahl, Jason Myers, Brady Culver, Brian Kudlow
  • Patent number: 10696721
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao
  • Patent number: 10689414
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 23, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Patent number: 10640569
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor(CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 5, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 10603309
    Abstract: A novel function for the p53 gene related to resolution of deep venous thrombosis is disclosed herein. Lack of the p53 gene results in impaired thrombus resolution in a clinically relevant in vivo model of deep venous thrombus resolution. It is further shown that augmentation of p53 activity with quinacrine accelerates thrombus resolution in vivo, and that this beneficial effect is completely dependent on p53. p53-based therapy is therefore provided to accelerate thrombus resolution in patients, and to prevent or ameliorate the debilitating long-term complications of deep venous thrombosis such as post-thrombotic syndrome.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 31, 2020
    Inventor: Rajabrata Sarkar
  • Patent number: 10568868
    Abstract: The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: February 25, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Jonathan Powell
  • Patent number: 10548985
    Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 4, 2020
    Assignee: Birdie Biopharmaceuticals, Inc.
    Inventor: Lixin Li
  • Patent number: 10550179
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 4, 2020
    Assignees: Lentigen Technology Inc., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10544201
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen ROR1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen ROR1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially chronic lymphocytic leukemia or solid tumors.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 28, 2020
    Assignee: CELLECTIS
    Inventor: Cècile Schiffer-Mannioui
  • Patent number: 10538591
    Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: January 21, 2020
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Mariano S. Viapiano, Nandhu Mohan Sobhana, Ennio Antonio Chiocca
  • Patent number: 10519233
    Abstract: The present invention aims to provide: an immunostimulant useful for maintaining, enhancing or suppressing an immune function associated with CD300a activation signaling, or an immunomodulator as an immunosuppressant useful for suppressing the immune function; use of a CD300a gene-deficient mouse for pathology analysis and the like; an anti-CD300a antibody; and the like.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: December 31, 2019
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Akira Shibuya, Chigusa Oda, Satoko Tahara, Tsukasa Nabekura, Udayanga Sanath Kankanam Gamage, Haruka Miki, Syuichi Iino
  • Patent number: 10487126
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 31, 2018
    Date of Patent: November 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10435681
    Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Nadav Orr, Yair Pilpel, Sivan Doron
  • Patent number: 10426822
    Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: October 1, 2019
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • Patent number: 10413586
    Abstract: An antiviral agent containing recombinant mistletoe lectins for treating virus infections and a medicament and/or pharmaceutical composition for treating virus infections are described. Recombinant mistletoe lectin polypeptides can be a mistletoe lectin A-chain, as well as parts or fragments of the mistletoe lectin A-chain. The antiviral agent can be used for any number of virus infections, such as Herpes simplex, adenovirus, poliovirus, and poxvirus. Also, the antiviral agent can be used for skin virus warts, anogenital warts, mucous membrane warts and malignant tumors such as cervical cancer, penis and vulvar cancer.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: September 17, 2019
    Assignee: Melema Pharma GmbH
    Inventors: Hans Lentzen, Klaus Witthohn
  • Patent number: 10383931
    Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 20, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
  • Patent number: 10364270
    Abstract: Disclosed is related to a synthetic peptide consisting of an amino acid sequence of ArgAsnProLeuGluGluThr (SEQ ID NO: 1). Also provided are a pharmaceutical composition benefic to eye care or eye health comprising the peptide, and a method for wound healing using the peptide.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 30, 2019
    Assignee: PRO SUNFUN BIOTECH RESEARCH AND DEVELOPMMENT CO., LTD.
    Inventors: Min-Chuan Huang, Syue-Ting Chen, Yu-Chun Liu
  • Patent number: 10357538
    Abstract: The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 23, 2019
    Assignee: NORTHERN SYDNEY LOCAL HEALTH DISTRICT
    Inventors: Ross Arthur Davey, Christopher John Weir
  • Patent number: 10350262
    Abstract: The invention relates, in part, to compounds, compositions, and methods useful to treat cancer in cells and subjects. In some aspects the invention includes contacting a cancer cell with one or more exogenous methylation-controlled J protein (MCJ) agonist compounds to increase sensitivity of the cancer cell to one or more chemotherapeutic agents. In certain aspects the invention includes compounds and methods useful to kill cancer cells.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 16, 2019
    Assignee: University of Vermont and State Agricultural College
    Inventors: Mercedes Rincon, Thomas Roberts, Tina Thornton
  • Patent number: 10350260
    Abstract: The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: July 16, 2019
    Assignee: Susavion Biosciences, Inc.
    Inventors: Laura L. Eggink, J. Kenneth Hoober
  • Patent number: 10344065
    Abstract: A method for treating Alzheimer's disease and a method for downregulating protein aggregation in brain are disclosed, which respectively comprises: administering a zinc finger-like peptide to a subject in need thereof, wherein the zinc finger-like peptide comprises an amino acid sequence of RRSSSCK (SEQ ID NO: 1).
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 9, 2019
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Nan-Shan Chang, Yu-Min Kuo
  • Patent number: 10336778
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON). The disclosure also provides compounds having formula (I) for use in treating cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 2, 2019
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i.
    Inventors: Barbara Slusher, Rana Rais, Lukas Tenora, Pavel Majer, Andrej Jancarik
  • Patent number: 10316077
    Abstract: Provided are cell-penetrating ATF5 polypeptides having a cell-penetrating region and an ATF5 leucine zipper region, compositions comprising the ATF5 polypeptides, and methods of treating a tumor and promoting cytotoxicity in a neoplastic cell using the ATF5 polypeptides.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: June 11, 2019
    Assignee: Sapience Therapeutics, Inc.
    Inventors: Barry Jay Kappel, Jimmy Andrew Rotolo, Gene Merutka
  • Patent number: 10294276
    Abstract: The present invention describes a process for isolation of romidepsin from fermentation broth and preparation of crystals of romidepsin. The process of the invention includes fewer purification steps and provides romidepsin having purity of greater than 99.5% area by HPLC. The process of the invention involves simple purification steps and hence, does not require multiple chromatographic purification steps to achieve desired quality of romidepsin. The process is advantageous over reported processes in terms of 99.5% pure yield, fast process, less expensive and less cumbersome as multiple chromatographic purification is not necessary to achieve desired quality. The process for the preparation of crystals of romidepsin provides advantages like simple steps and involves use of single solvent. The process is advantageous in terms of time, cost, and simplicity.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: May 21, 2019
    Assignee: Concord Biotech Limited
    Inventors: Ankur S. Vaid, Anand M. Dhiman, Traunkant P. Sharma
  • Patent number: 10292992
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 21, 2019
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10293024
    Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: May 21, 2019
    Assignee: Blueberry Therapeutics Limited
    Inventor: John Ridden
  • Patent number: 10221417
    Abstract: The present invention relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3; and/or (ii) a compound inhibiting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42. The present invention also relates to a pharmaceutical composition comprising (i) a compound promoting the expression and/or the activity of one or more lncRNAs selected from SEQ ID NOs 23 to 42; and/or (ii) a compound inhibiting the expression and/or the activity of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 22, preferably selected from SEQ ID NOs 1 to 3.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: March 5, 2019
    Assignee: MEDIZINISCHE HOCHSCHULE HANNOVER
    Inventors: Thomas Thum, Jan Fiedler
  • Patent number: 10206975
    Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Swedish Orphan Biovitrum AB (PUBL)
    Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
  • Patent number: 10202456
    Abstract: Provided is a recombinant cell including inactivated pyruvate dehydrogenase kinase (PDK) gene, a composition for producing a polypeptide of interest including the recombinant cell, and a method of producing a polypeptide of interest using the recombinant cell.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: February 12, 2019
    Assignee: Samsung Bioepis Co., Ltd.
    Inventors: Eunyoung Park, Hye Young Suh, Hee Kyung Sung, Christina Yi, Sunkyu Kim
  • Patent number: 10196432
    Abstract: The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
    Type: Grant
    Filed: September 5, 2006
    Date of Patent: February 5, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventor: Jörn Dengiel